FRMPD4

Across TCGA pan-cancer cohorts, FRMPD4 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated FRMPD4 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher FRMPD4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FRMPD4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, KIRP, and COAD are the cancer types where FRMPD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.248	0.543	.006	18	view →
KIRP	OS	Median	All	0.216	0.904	<.001	15	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	13	view →
LGG	OS	Median	All	0.483	0.898	<.001	10	view →
UCEC	OS	Median	II,III,IV	0.868	0.453	.028	10	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	8	view →
ACC	DFS	Median	All	0.195	0.748	.003	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	IV	0.193	0.598	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

FRMPD4–OV (DFS)

Open the OV breakdown →